Status:
TERMINATED
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Lead Sponsor:
Dallas VA Medical Center
Collaborating Sponsors:
TAP Pharmaceutical Products Inc.
Conditions:
Gastroesophageal Reflux Disease
Eosinophilic Esophagitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Background: Up to 40% of patients who are treated with PPIs for symptoms that are thought to be due to GERD experience only incomplete relief of their symptoms. Those patients are deemed "PPI failures...
Eligibility Criteria
Inclusion
- Male and female patients ages 18 years and older who are referred to the Division of Gastroenterology at the Dallas VA Medical Center for the evaluation of heartburn that is refractory to PPI therapy
Exclusion
- Patients unwilling or unable to provide informed consent.
- Allergy to lansoprazole.
- Patients taking warfarin.
- Coagulopathy that precludes safe biopsy of the esophagus.
- Comorbidity that precludes safe participation in the study.
- Pregnancy.
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT01404832
Start Date
October 1 2007
End Date
May 1 2010
Last Update
February 27 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dallas VA Medical Center
Dallas, Texas, United States, 75216